06118.HK
Austar Lifesciences Limited
HKSE · Healthcare · Medical - Devices · CN
HKD 0.70
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.1B | 1.5B | 1.5B | 1.8B | 2.2B |
| Cost of Revenue | 2.5B | 1.2B | 1.2B | 1.4B | 1.8B |
| Gross Profit | 585.3M | 293.3M | 301.2M | 336.1M | 488.8M |
| Operating Expenses | |||||
| R&D Expense | 92.3M | 45.1M | 53.5M | 55.3M | 70.2M |
| SG&A Expense | 464.0M | 225.0M | 239.1M | 301.0M | 305.9M |
| General & Admin Expense | 141.4M | 85.4M | 107.2M | 133.7M | 128.8M |
| Selling & Marketing Expense | 207.5M | 139.6M | 131.9M | 167.3M | 177.1M |
| Other Expenses | (50.3M) | (30.9M) | (26.6M) | 9.7M | (3.7M) |
| Total Operating Expenses | 506.0M | 239.1M | 266.0M | 366.0M | 372.4M |
| Cost and Expenses | 3.0B | 1.5B | 1.5B | 1.8B | 2.0B |
| Operating Income (EBIT) | 79.3M | 54.2M | 35.2M | (30.0M) | 116.4M |
| Non-Operating | |||||
| Interest Income | 3.5M | 1.4M | 2.9M | 3.1M | 2.3M |
| Interest Expense | 22.5M | 11.8M | 17.2M | 14.0M | 9.6M |
| Net Interest Income | (21.4M) | (10.4M) | (14.3M) | (10.9M) | (7.3M) |
| Other Non-Op Income/Expense | (1.8M) | (6.0M) | (14.0M) | (4.4M) | 3.2M |
| Non-Operating Income (excl Interest) | 14.0M | 11.1M | 410.0K | (9.5M) | (6.4M) |
| EBT (Pre-Tax Income) | 77.5M | 48.1M | 21.2M | (34.4M) | 119.5M |
| Income Tax Expense | 26.5M | 15.2M | 7.6M | 379.0K | 18.9M |
| Bottom Line | |||||
| Net Income | 52.4M | 33.8M | 16.1M | (113.5M) | 87.5M |
| Earnings from Cont. Ops | 51.0M | 32.9M | 13.6M | (34.8M) | 100.6M |
| Earnings from Discont. Ops | — | — | — | (80.9M) | (16.8M) |
| Bottom Line Net Income | 52.4M | 33.8M | 16.1M | (113.5M) | 104.2M |
| Per Share | |||||
| Basic EPS | HK$0.10 | HK$0.07 | HK$0.03 | (HK$0.22) | HK$0.17 |
| Diluted EPS | HK$0.10 | HK$0.07 | HK$0.03 | (HK$0.22) | HK$0.17 |
| Revenue Per Share | HK$5.98 | HK$2.99 | HK$2.93 | HK$3.44 | HK$4.21 |
| Shares | |||||
| Basic Shares Outstanding | 512.6M | 512.6M | 512.6M | 512.6M | 512.6M |
| Diluted Shares Outstanding | 512.6M | 512.6M | 512.6M | 512.6M | 512.6M |
| Profitability Metrics | |||||
| EBITDA | 141.0M | 73.1M | 70.7M | 25.1M | 159.8M |
| D&A | 75.7M | 30.0M | 35.9M | 45.6M | 37.0M |
| EBIT | 65.3M | 43.1M | 34.8M | (20.4M) | 122.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026